Tango Therapeutics (NASDAQ:TNGX) Now Covered by Analysts at Mizuho

Analysts at Mizuho started coverage on shares of Tango Therapeutics (NASDAQ:TNGX) in a research report issued on Monday. The brokerage set an “outperform” rating and a $19.00 price target on the stock. Mizuho’s price target indicates a potential upside of 55.74% from the stock’s current price.

TNGX has been the topic of several other reports. Wall Street Zen raised Tango Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, December 13th. Stifel Nicolaus began coverage on Tango Therapeutics in a report on Wednesday, December 3rd. They set a “buy” rating and a $15.00 price target for the company. Piper Sandler upped their price objective on Tango Therapeutics from $11.00 to $14.00 and gave the stock an “overweight” rating in a report on Friday, January 16th. Wolfe Research initiated coverage on shares of Tango Therapeutics in a report on Tuesday, November 18th. They issued a “peer perform” rating for the company. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Tango Therapeutics in a research report on Monday, October 27th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $15.50.

Tango Therapeutics Stock Down 1.2%

NASDAQ TNGX opened at $12.20 on Monday. Tango Therapeutics has a twelve month low of $1.03 and a twelve month high of $13.48. The business has a 50-day moving average price of $11.01 and a 200-day moving average price of $9.04. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of -13.12 and a beta of 1.75.

Insider Activity at Tango Therapeutics

In related news, Director Barbara Weber sold 30,519 shares of the stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total value of $374,162.94. Following the sale, the director directly owned 1,629,254 shares of the company’s stock, valued at $19,974,654.04. This represents a 1.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Daniella Beckman sold 10,317 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total transaction of $126,486.42. Following the completion of the sale, the chief financial officer directly owned 184,297 shares of the company’s stock, valued at approximately $2,259,481.22. The trade was a 5.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 59,288 shares of company stock worth $726,871. Insiders own 7.50% of the company’s stock.

Hedge Funds Weigh In On Tango Therapeutics

Several hedge funds have recently bought and sold shares of the business. CWM LLC lifted its stake in Tango Therapeutics by 182.2% in the second quarter. CWM LLC now owns 4,905 shares of the company’s stock worth $25,000 after acquiring an additional 3,167 shares during the period. Global Retirement Partners LLC purchased a new stake in shares of Tango Therapeutics in the 4th quarter worth approximately $35,000. Dynamic Technology Lab Private Ltd boosted its stake in shares of Tango Therapeutics by 139.7% during the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock valued at $35,000 after purchasing an additional 15,037 shares in the last quarter. Legal & General Group Plc increased its holdings in Tango Therapeutics by 30.7% during the second quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock valued at $36,000 after buying an additional 1,640 shares during the period. Finally, Ameritas Investment Partners Inc. raised its stake in Tango Therapeutics by 78.8% in the second quarter. Ameritas Investment Partners Inc. now owns 7,830 shares of the company’s stock worth $40,000 after buying an additional 3,452 shares in the last quarter. Institutional investors own 78.99% of the company’s stock.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.